Welcome to our dedicated page for Hamilton Thorne news (Ticker: HTLZF), a resource for investors and traders seeking the latest updates and insights on Hamilton Thorne stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hamilton Thorne's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hamilton Thorne's position in the market.
Hamilton Thorne announced the completion of its going private transaction with Cradle Acquisition ULC, an acquisition vehicle managed by Astorg. The transaction involved the purchase of all issued and outstanding common shares at C$2.25 per share, excluding certain shares held by Daniel Thorne and FAX Capital Corp. Following the transaction, the shares will be delisted from the TSX, and the company will cease to be a reporting issuer in Canada. Registered shareholders who haven't done so are advised to submit their letter of transmittal and share certificates to Computershare Investor Services.
Hamilton Thorne reported strong Q3 2024 financial results with revenue growing 24% to $19.4 million and Adjusted EBITDA increasing 72% to $3.7 million. The company achieved 14% organic growth for the quarter, with equipment sales up 20% and consumables, software, and services growing over 27%. Despite posting a net loss of $1.18 million for the quarter, gross profit increased 27% to $9.7 million. The company generated $3.5 million in operating cash flow for the nine months and maintains $6.9 million cash on hand. Management confirmed 2024 guidance with expected sales between $78-82 million, representing 10-15% organic growth. The company expects to complete its going private transaction on November 29, 2024.
Hamilton Thorne (TSX: HTL), a leading provider in the Assisted Reproductive Technologies (ART) field, has provided an update on its going private transaction with Cradle Acquisition Key points include:
- The transaction was approved by shareholders on September 17, 2024
- Final court approval was obtained on September 20, 2024
- Definitive agreements have been signed for the acquisition of Cook Medical's ART product portfolio
- All required regulatory approvals have been obtained
- The transaction and acquisition are expected to close on November 30, 2024
- Hamilton Thorne's shares will be delisted from the TSX upon closing
The company will also apply to cease being a reporting issuer in Canada.
Summary not available.
Summary not available.